Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

Inclusion Criteria: * Age ≥ 18 years of age * Creatinine ≤1.5 mg/100 ml or creatinine clearance ≥ 45ml/min/m2 , direct bilirubin ≤2.0 mg/100 ml, AST and ALT ≤3.0x upper limit of normal (ULN) * Adequate pulmonary function as assessed by ≥92% oxygen saturation on room air by pulse oximetry. * Histologically confirmed DLBCL and large B cell lymphoma, including * DLBCL, not otherwise specified (NOS), or * Transformed DLBCL from follicular lymphoma, or * High-grade B cell lymphoma (excluding Burkitt's lymphoma), or * Primary mediastinal large B cell lymphoma AND * Chemotherapy refractory disease, defined as a failure to achieve at least a partial response or disease progression within 12 months to the last therapy, OR * Disease progression or recurrence in ≤12 months of prior autologous stem cell transplant (ASCT), OR * Relapsed disease after 2 or more prior chemoimmunotherapies with at least one containing an anthracycline and CD20 directed therapy * Patients need to have radiographically documented disease Exclusion Criteria: * ECOG performance status ≥2. * Pregnant or lactating women. Women and men of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finished. * Active CNS disease * Impaired cardiac function (LVEF \<40%) as assessed by ECHO or MUGA scan. * Patients with the following cardiac conditions will be excluded: * New York Heart Association (NYHA) stage III or IV congestive heart fa…